Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi’s Hyaluronic Acid Program. Alpha was selected as an ALOHA launch partner for its demonstrated commitment to innovation, education, collaboration, and advancing aesthetic medicine through scalable, high-quality care models. Through this real-world evaluation collaboration, Alpha will conduct a structured, multi-site evaluation of Obagi saypha MagIQ across its network of practices. The program will leverage Alpha’s strengths in systematic education, patient satisfaction, and cross-practice culture to generate real-world evidence demonstrating the value of integrating Obagi’s first FDA-approved injectable hyaluronic acid filler into diverse clinical environments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Obagi Medical, Platinum Dermatology Partners collaborate for ALOHA program
- Obagi Medical unveils ALOHA Program to launch saypha MagIQ
- Waldencast Shareholders Back Board Slate and Auditor at January 2026 AGM
- Waldencast assumed with a Buy at Jefferies
- Waldencast Sets January 2026 AGM and Reshapes Board Following Director Resignations
